Geode Capital Management LLC Has $1.33 Billion Holdings in Becton, Dickinson and Company $BDX

Geode Capital Management LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,885,361 shares of the medical instruments supplier’s stock after buying an additional 53,884 shares during the quarter. Geode Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $1,331,165,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Oppenheimer Asset Management Inc. raised its stake in Becton, Dickinson and Company by 71.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after acquiring an additional 34,437 shares during the period. Transcend Capital Advisors LLC raised its stake in Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after acquiring an additional 2,715 shares during the period. Assetmark Inc. raised its stake in Becton, Dickinson and Company by 49.5% in the 3rd quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after acquiring an additional 74,795 shares during the period. Finally, Belpointe Asset Management LLC bought a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $650,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.8%

Shares of NYSE BDX opened at $148.36 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The stock has a market capitalization of $40.88 billion, a P/E ratio of 37.56, a PEG ratio of 10.42 and a beta of 0.22. The stock’s fifty day moving average is $151.84 and its 200 day moving average is $177.23.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter last year, the business earned $3.35 earnings per share. Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Analysts Set New Price Targets

Several research analysts have weighed in on BDX shares. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. lowered their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Piper Sandler lowered their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Finally, Royal Bank Of Canada set a $175.00 price objective on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $183.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.